You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

153 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Curative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
ODB - General Benefit
    dexamethasone
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
Jun 2020
Regimen
Cancer Type:
Genitourinary, 
Testis
Intent: Curative, Adjuvant
Sep 2017
Regimen
Cancer Type:
Central Nervous System
Intent: Adjuvant, Curative, Palliative
Funding:
ODB - General Benefit
    procarbazine
ODB - General Benefit
    lomustine
Jan 2023
Regimen
Intent: Curative, Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Apr 2023
Regimen
Cancer Type:
Gynecologic, 
Cervix
Intent: Adjuvant, Curative
May 2025
Regimen
Cancer Type:
Sarcoma, 
Desmoid Tumour
Intent: Curative
Funding:
ODB - General Benefit
    tamoxifen
May 2019
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Intent: Curative
Nov 2017
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Intent: Adjuvant, Curative, Palliative
Aug 2020
Regimen
Cancer Type:
Central Nervous System
Intent: Curative, Palliative
Mar 2025
Regimen
Cancer Type:
Genitourinary, 
Testis
Intent: Curative
Mar 2021
Regimen
Cancer Type:
Lung, 
Mesothelioma (Pleural)
Intent: Curative, Palliative
Oct 2024
Regimen
Cancer Type:
Genitourinary, 
Testis
Intent: Curative
Apr 2016

Pages